Computational analysis of the binding specificity of Gleevec to Abl, c-Kit, Lck, and c-Src tyrosine kinases

Yen-Lin Lin1, Benoît Roux

  • 1Department of Biochemistry and Molecular Biology, Gordon Center for Integrative Science, The University of Chicago , 929 57th Street, Chicago, Illinois 60637, United States.

Insights

Gleevec effectively inhibits Abl and c-Kit kinases but not Lck or c-Src due to subtle structural differences. Free energy simulations reveal van der Waals interactions and kinase activation loop conformation dictate Gleevec

Area of Science:

  • Biochemistry
  • Computational Biology
  • Pharmacology

Background:

  • Gleevec is a cancer drug inhibiting tyrosine kinases like Abl and c-Kit.
  • Its lower potency against homologous kinases (Lck, c-Src) is poorly understood.
  • Conserved binding sites complicate Gleevec's specificity determinants.

Purpose of the Study:

  • To computationally determine Gleevec's binding affinity to Abl, c-Kit, Lck, and c-Src.
  • To dissect the thermodynamic contributions to Gleevec's kinase binding specificity.
  • To elucidate the molecular basis for Gleevec's differential inhibition of kinases.

Main Methods:

  • Free energy perturbation molecular dynamics (FEP/MD) simulations with explicit solvent.
  • Calculation of absolute binding free energies for Gleevec with four kinases.
  • Analysis of thermodynamic contributions (van der Waals, electrostatic, entropic penalties).

Main Results:

  • FEP/MD results align well with experimental data.
  • Van der Waals interactions are the dominant favorable contribution to binding.
  • Kinase activation loop conformation significantly impacts Gleevec binding.
  • Abl offers the most favorable binding environment for Gleevec.
  • Lck and c-Src show similar non-binding interactions but differ in entropic penalties.

Conclusions:

  • FEP/MD simulations successfully explain Gleevec's differential kinase binding.
  • Binding specificity is governed by a balance of van der Waals forces and entropic costs.
  • Protein-ligand interactions and conformational flexibility are key determinants of Gleevec's efficacy.